Drug Profile

iQ 007

Alternative Names: iQ-007

Latest Information Update: 17 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator iQure Pharma
Class Antiepileptic drugs; Non-opioid analgesics; Small molecules
Mechanism of Action Excitatory amino acid transporter 2 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Dravet syndrome
New Molecular Entity Yes

Highest Development Phases

Phase I Epilepsy
No development reported Neuropathic pain

Most Recent Events

14 Oct 2025 iQure Pharma partnered and the University of Padova agree to co-develop iQ 007 to study the mechanism and accelerate precision therapies for CNS disorders
29 Sep 2025 iQure Pharma has patent protection for iQ 007 in USA
08 Apr 2025 Phase-I clinical trials in Epilepsy (In volunteers) in Australia (PO) (NCT06899230)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com